Immunic's Vidofludimus Calcium Shows Promising Results for Progressive Multiple Sclerosis at ECTRIMS 2025

Immunic Showcases Promising Data on Vidofludimus Calcium at ECTRIMS 2025

Immunic, Inc., a biotechnology firm dedicated to developing oral therapies for chronic inflammatory and autoimmune diseases, draws attention to its lead asset, vidofludimus calcium (IMU-838), at the recent 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona. The results presented from the Phase 2 CALLIPER trial reflect significant advancements in treating progressive multiple sclerosis (PMS), a condition that currently lacks effective therapeutic options. The trial's findings suggest a statistically significant improvement in confirmed disability after 24 weeks of treatment, with vidofludimus calcium demonstrating over a two-fold probability of efficacy compared to placebo. This positions the drug as a potential game-changer for patients grappling with PMS.

The CALLIPER trial results, which earned recognition in the Best of ECTRIMS 2025 slide deck, showcase the drug's ability to slow disability progression across various patient subgroups. Notably, patients without focal inflammation exhibited promising improvements, suggesting that vidofludimus calcium may possess neuroprotective properties critical for managing PMS. The data underscores the high unmet medical need within this patient population, highlighting the therapeutic potential of Immunic’s approach. Dr. Daniel Vitt, CEO of Immunic, presents the findings as a pivotal moment for the company, emphasizing their commitment to addressing the challenges faced by individuals suffering from progressive forms of multiple sclerosis.

In addition to the CALLIPER trial, Immunic shares long-term safety and efficacy data from its Phase 2 EMPhASIS trial, which focuses on relapsing-remitting multiple sclerosis (RRMS). This trial reveals high percentages of patients remaining free from confirmed disability worsening at both 12 and 24 weeks, coupled with low discontinuation rates. The safety profile observed is favorable, further reinforcing Immunic’s stance on the viability of vidofludimus calcium as a transformative oral therapy in the multiple sclerosis landscape.

The presentations at ECTRIMS underline Immunic's significant advancements in the field, providing a beacon of hope for patients affected by chronic inflammatory conditions. As the company continues to develop innovative solutions, it remains poised to make a meaningful impact in the treatment of multiple sclerosis. For further details, the presentations are accessible on Immunic's official website.